Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Dec 9;2022(1):421-423.
doi: 10.1182/hematology.2022000400.

Novel platelet products including cold-stored platelets

Dana V Devine  1
Affiliations
Review

Novel platelet products including cold-stored platelets

Dana V Devine. Hematology Am Soc Hematol Educ Program. .

Abstract

This article reviews 3 products: pathogen-inactivated platelets, cold-stored platelets, and cryoplatelets. These are all coming to a transfusion service near you in the next few years. The article reviews the limitations of these new products and highlights the gaps in our understanding of their place in patient treatment.

PubMed Disclaimer

Conflict of interest statement

Dana V. Devine is the chair of the Scientific Advisory Board of Macopharma, a French company working in the transfusion medicine space; an employee of Canadian Blood Services; chair of the medical advisory committee of the American Red Cross; on the board of directors of STRM.Bio, a Boston-based gene therapy company; and currently the president of the AABB.

Figures

None
Graphical abstract
See this image and copyright information in PMC

References

    1. van Rhenen D, Gulliksson H, Cazenave J-P, et al; EuroSPRITE trial. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the EuroSPRITE trial. Blood. 2003;101(6):2426-2433. doi: 10.1182/blood-2002-03-0932. - DOI - PubMed
    1. Snyder E, McCullough J, Slichter SJ, et al; SPRINT Study Group. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion. 2005;45(12):1864-1875. doi: 10.1111/j.1537-2995.2005.00639.x. - DOI - PubMed
    1. Schubert P, Culibrk B, Karwal S, et al.. Whole blood treated with riboflavin and ultraviolet light: quality assessment of all blood components produced by the buffy coat method. Transfusion. 2015;55(4):815-823. doi: 10.1111/trf.12895. - DOI - PubMed
    1. Saris A, Kerkhoffs JL, Norris PJ, et al.. The role of pathogen-reduced platelet transfusions on HLA alloimmunization in hemato-oncological patients. Transfusion. 2019;59(2):470-481. doi: 10.1111/trf.15056. - DOI - PubMed
    1. Ypma PF, van der Meer PF, Heddle NM, et al; PREPAReS study group. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open. 2016;6(1):e010156. doi: 10.1136/bmjopen-2015-010156. - DOI - PMC - PubMed